Evidence map›Paper›PMID 35288568›Full record

ArticleNature communications2022

β

Eun-A Kwak, Christopher C Pan, Aaron Ramonett, Sanjay Kumar, Paola Cruz-Flores, Tasmia Ahmed, Hannah R Ortiz, Jeffrey J Lochhead, Nathan A Ellis, Ghassan Mouneimne and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Eun-A Kwak *Department of Pharmacology, University of Arizona, Tucson, AZ, 85724, USA.
Christopher C Pan *Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, 27710, USA.
Aaron RamonettDepartment of Pharmacology, University of Arizona, Tucson, AZ, 85724, USA.
Sanjay KumarDivision of Biology, Indian Institute of Science Education and Research, Tirupati, 517507, India.ORCID http://orcid.org/0000-0001-9238-2349
Paola Cruz-FloresDepartment of Chemistry & Biochemistry, University of Arizona, Tucson, AZ, 85724, USA.
Tasmia AhmedDepartment of Chemistry & Biochemistry, University of Arizona, Tucson, AZ, 85724, USA.
Hannah R OrtizDepartment of Pharmacology, University of Arizona, Tucson, AZ, 85724, USA.
Jeffrey J LochheadDepartment of Pharmacology, University of Arizona, Tucson, AZ, 85724, USA.
Nathan A EllisCellular and Molecular Medicine, University of Arizona, Tucson, AZ, 85724, USA.
Ghassan MouneimneCellular and Molecular Medicine, University of Arizona, Tucson, AZ, 85724, USA.
Teodora G GeorgievaBIO5 Institute, University of Arizona, Tucson, AZ, 85724, USA.
Yeon Sun LeeDepartment of Pharmacology, University of Arizona, Tucson, AZ, 85724, USA.
Todd W VanderahDepartment of Pharmacology, University of Arizona, Tucson, AZ, 85724, USA.
Tally Largent-MilnesDepartment of Pharmacology, University of Arizona, Tucson, AZ, 85724, USA.
Peter J MohlerDepartment of Physiology and Cell Biology, Ohio State University, Columbus, OH, 43210, USA.
Thomas J HundDepartment of Biomedical Engineering, Ohio State University, Columbus, OH, 43210, USA.
Paul R LanglaisDepartment of Internal Medicine, University of Arizona, Tucson, AZ, 85724, USA.
Karthikeyan MythreyeDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Nam Y LeeDepartment of Pharmacology, University of Arizona, Tucson, AZ, 85724, USA. namlee@email.arizona.edu.ORCID http://orcid.org/0000-0002-3730-0774
University of Arizona · USThe Ohio State University · USDuke University · USIndian Institute of Science Education and Research, Tirupati · INUniversity of Alabama at Birmingham · US

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Teri L Bankhead · 1985 to 2026
$110.2M
The Center of Excellence in Addiction Studies (CEAS)P30DA051355 · NIDA · UNIVERSITY OF ARIZONA · PI PORRECA, FRANK, VANDERAH, TODD W · 2021 to 2025
$6.7M
Inhibin function in tumor angiogenesisR01CA219495 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI KARTHIKEYAN, MYTHREYE · 2018 to 2023
$1.7M
Role of spectrin signaling complex in angiogenesisR01GM128055 · NIGMS · UNIVERSITY OF ARIZONA · PI LEE, NAM Y · 2019 to 2022
$1.3M
Primary Afferent Transmission in the Trigeminal Dorsal HornF32DE022499 · NIDCR · OREGON HEALTH & SCIENCE UNIVERSITY · PI MILNES, TALLY MARIE · 2011 to 2014
$127k
NCI NIH HHS P30 CA023074NCI NIH HHS R01 CA219495NIDA NIH HHS P30 DA051355NIDCR NIH HHS F32 DE022499NIGMS NIH HHS R01 GM128055
6 · The paper itself

Abstract

Defective angiogenesis underlies over 50 malignant, ischemic and inflammatory disorders yet long-term therapeutic applications inevitably fail, thus highlighting the need for greater understanding of the vast crosstalk and compensatory mechanisms. Based on proteomic profiling of angiogenic endothelial components, here we report β

Indexed as

SpectrinVascular Endothelial Growth Factor AAnimalsCalcium-Calmodulin-Dependent Protein Kinase Type 2MiceNeovascularization, PhysiologicProteomicsSignal TransductionVascular Endothelial Growth Factor Receptor-2Calcium-Calmodulin-Dependent Protein Kinase Type 2SpectrinVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2

Identifiers

PMID35288568
PMCPMC8921520
OpenAlexW4221036237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.